Grading and Management of IBD Flares
For ulcerative colitis, mild-to-moderate disease is defined as <4-6 bowel movements per day with mild-moderate rectal bleeding and absence of constitutional symptoms, while severe disease requires hospitalization with ≥7 bowel movements per day, severe abdominal pain, and peritoneal signs; for Crohn's disease, moderate-to-severe disease requiring hospitalization should receive IV methylprednisolone 40-60 mg/day with response assessed within 72 hours to determine need for rescue therapy or surgery. 1, 2, 3
Disease Severity Classification
Ulcerative Colitis Grading
Mild-to-Moderate UC:
- Stool frequency: <4-6 bowel movements per day
- Rectal bleeding: Mild-to-moderate (patient-reported outcome rectal bleeding score ≥2)
- Constitutional symptoms: Absent
- Inflammatory burden: Low overall
- Mayo endoscopic subscore: ≥2 (diffuse erythema, friability, erosions) 1, 4
Moderate-to-Severe UC:
- Stool frequency: ≥6-7 bowel movements per day
- Rectal bleeding: Prominent or spontaneous
- Mayo endoscopic subscore: ≥3 (spontaneous bleeding or ulcerations)
- May have constitutional symptoms
- Higher inflammatory burden 1, 4
Severe UC (Hospitalization Required):
- Stool frequency: ≥7 bowel movements per day
- Severe abdominal pain with peritoneal signs
- Change in bowel habits requiring medical intervention
- Hemodynamic instability possible 3, 5
Crohn's Disease Grading
Moderate-to-Severe CD:
- CDAI score: Most commonly 220-450 (though definitions vary from 200-450)
- Disease severity sufficient to require hospitalization
- Failed outpatient corticosteroid, thiopurine, or methotrexate therapy
- Presence of complications (obstruction, abscess, fistula) 2, 6
High-Risk Features (Predict Aggressive Course):
- Age <40 years at diagnosis
- Extensive disease
- Severe endoscopic activity (deep ulcers)
- Extraintestinal manifestations
- Elevated inflammatory markers (CRP, ESR, fecal calprotectin) 1
Management Algorithm by Severity
Mild-to-Moderate UC (Outpatient)
First-Line Therapy:
- Oral AND rectal 5-ASA combination therapy (superior to either alone)
- Extensive disease: Oral mesalamine ≥2.4 g/day
- Left-sided disease: Oral mesalamine + rectal mesalamine
- Proctitis: Rectal mesalamine suppositories 1, 5
If No Response in 2-4 Weeks:
- Add oral corticosteroids (prednisone 40-60 mg/day)
- Taper over 8-12 weeks once symptomatic remission achieved
- Critical: Avoid repeated corticosteroid courses—escalate to advanced therapy if requiring steroids >2 times per year 1, 5
Corticosteroid-Dependent/Resistant:
- Initiate anti-TNF therapy (infliximab, adalimumab, golimumab)
- Alternative: Vedolizumab, JAK inhibitors (tofacitinib, upadacitinib), S1P modulators (ozanimod, etrasimod), or IL-12/23 inhibitors (ustekinumab, risankizumab, guselkumab)
- Higher efficacy options for treatment-naïve patients: Infliximab, vedolizumab, upadacitinib, ozanimod, etrasimod, risankizumab, guselkumab 4
Moderate-to-Severe UC (Hospitalization Required)
Initial Management (Day 1):
- IV methylprednisolone 60 mg/day (or equivalent)
- Supportive care: IV fluids, electrolyte correction, VTE prophylaxis with LMWH
- Rule out C. difficile infection (stool assay), CMV reactivation (colonic tissue immunohistochemistry or PCR from ≥11 left colon samples)
- Avoid antibiotics unless superinfection/abscess present
- Early surgical consultation 3, 5, 7
Response Assessment (Day 3):
- Evaluate clinical response: stool frequency, rectal bleeding, abdominal pain
- Check inflammatory markers: CRP, ESR
- Stool frequency >8/day or CRP >45 mg/L on day 3 predicts colectomy need 3, 5
If No Improvement by Day 3-5:
- Initiate rescue therapy:
- Option 1: Infliximab 5 mg/kg IV (can repeat after 2 weeks if needed) + thiopurine
- Option 2: Cyclosporine 2-4 mg/kg/day IV (requires therapeutic drug monitoring)
- If rescue therapy fails or patient deteriorates: Proceed to colectomy 3, 5
Moderate-to-Severe Crohn's Disease (Hospitalization Required)
Initial Management:
- IV methylprednisolone 40-60 mg/day
- Assess for complications:
- Obstruction: CT/MRI to differentiate inflammatory vs. fibrotic stricture
- Abscess: CT-guided drainage if >3 cm; antibiotics for all abscesses
- Perianal disease: MRI pelvis, examination under anesthesia
- Rule out infections (C. difficile, CMV, bacterial cultures)
- VTE prophylaxis, nutritional assessment 2, 3
Response Assessment (Within 1 Week):
- Evaluate symptomatic response to IV corticosteroids
- If no improvement: Modify therapy 2
Corticosteroid-Refractory/Dependent CD:
- Anti-TNF therapy (infliximab, adalimumab) ± immunomodulator
- For patients with poor prognostic factors: Consider anti-TNF as first-line therapy
- Evaluate response at 8-12 weeks; if suboptimal, consider dose intensification guided by therapeutic drug monitoring 2
Complicated CD Management:
- Abscess >3 cm: Percutaneous drainage + antibiotics, delay anti-TNF until abscess resolved
- Abscess <3 cm: IV antibiotics with close monitoring
- Obstruction with active inflammation: IV corticosteroids; if fibrotic stricture or no response, surgical consultation
- Perianal fistulizing disease: Anti-TNF (infliximab or adalimumab) + surgical drainage/seton placement 3, 7
Critical Management Principles
Monitoring and Reassessment:
- UC: Assess response to IV steroids by day 3; initiate rescue therapy by day 5 if no improvement
- CD: Assess response to IV steroids within 1 week
- Anti-TNF therapy: Evaluate response at 8-12 weeks 2, 5
Infection Screening (Mandatory Before Escalation):
- C. difficile stool assay (all patients with flare)
- CMV tissue immunohistochemistry/PCR (steroid-refractory disease, hospitalized patients)
- Bacterial stool cultures, ova/cysts/parasites if travel history
- HIV, hepatitis B/C screening before immunosuppression 3, 8, 7
VTE Prophylaxis:
- All hospitalized IBD patients require pharmacologic VTE prophylaxis with LMWH
- IBD is independent risk factor for thromboembolism, especially during active disease 3, 7
Avoid These Pitfalls:
- Do NOT use corticosteroids for maintenance therapy (strong recommendation against) 2
- Do NOT delay surgical consultation in severe UC—early involvement improves outcomes 5, 7
- Do NOT start anti-TNF therapy in presence of undrained abscess >3 cm 3
- Do NOT use thiopurine monotherapy to induce remission in CD 2, 9
Discharge Criteria:
- Clinical stability achieved (reduced stool frequency, minimal bleeding, no fever)
- Tolerating oral intake
- Clear outpatient follow-up plan within 1-2 weeks
- Transition to oral/subcutaneous maintenance therapy initiated 7